Sintilimab combined with a bevacizumab biosimilar has improved survival when used as first-line treatment of advanced hepatocellular carcinoma (HCC) patients in comparison to sorafenib.
From a recent study, it was concluded that the combination of sintilimab and bevacizumab biosimilar has considerably enhanced survival.
In this study patients suffering from metastatic HCC were included. Three hundred-eighty patients were treated with sintilimab 200 mg given intravenously every three weeks along with a bevacizumab biosimilar 15 mg/kg given intravenously every three weeks. 191 patients were given oral sorafenib 400 mg two times a day. Stratification factors considered macrovascular invasion and/or extrahepatic metastasis, baseline alpha fetoprotein level and ECOG performance status.
The major outcomes were progression-free survival and overall survival by independent radiographic review committee, according to RECIST.
By median follow-up of 10.0 months, median overall survival was considerably longer with the sintilimab in combination with bevacizumab biosimilar as compared to sorafenib. The combination showed a 43.1% reduced risk of all-cause death.
Correspondingly, improved progression-free survival was also verified, with a 43.5% reduced risk of progression evaluated with IRRC. Median progression-free survival with the combination was 4.6 months and 2.8 months with sorafenib.
Overall the combination over sorafenib was supported. Treatment-related adverse events (TRAEs) took place in 88.7% of patients administering the combination against 93.5% of sorafenib-treated patients.
It was concluded that the sintilimab in combination with bevacizumab biosimilar demonstrated considerable improvements in comparison to sorafenib. It has shown benefits as first-line treatment for advanced HCC patients.
|Link to the source:||https://www.esmo.org/oncology-news/promising-results-observed-with-front-line-sintilimab-plus-a-bevacizumab-biosimilar-in-patients-with-advanced-hcc
[Last accessed on: 24 November, 2020]
|Original title of article:||Promising results observed with front-line sintilimab plus a bevacizumab biosimilar in patients with advanced HCC|
Disease area: Advanced hepatocellular carcinoma
Tags: Exploratory, Advanced hepatocellular carcinoma, Liver, Chronic, Phase III, Efficacy, Safety